BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS-Reference-Cited by-同舟云学术

BACILLUS CALMETTE-GUERIN VERSUS CHEMOTHERAPY FOR THE INTRAVESICAL TREATMENT OF PATIENTS WITH CARCINOMA IN SITU OF THE BLADDER: A META-ANALYSIS OF THE PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALS

Published:2005-07 Issue:1 Volume:174 Page:86-91
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

SYLVESTER RICHARD J.¹,van der MEIJDEN ADRIAN P.M.¹,WITJES J. ALFRED¹,KURTH KARLHEINZ¹

Affiliation:

1. From the European Organization for the Research and Treatment of Cancer Data Center, Brussels, Belgium, Jeroen Bosch Hospital, ‘s-Hertogenbosch, University Medical Center, Nijmegen, and the Academic Medical Center, Amsterdam, The Netherlands

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference23 articles.

1. Updated concepts and treatment of carcinoma in situ

2. The World Health Organization/International Society of Urological Pathology Consensus Classification of Urothelial (Transitional Cell) Neoplasms of the Urinary Bladder

3. Meta-analysis: The fashion of summing-up evidence

4. Experience with Bacillus Calmette-Guerin in Patients with Superficial Bladder Carcinoma

5. Intravesical 4′-epi-doxorubicin(epirubicin) versus bacillus calmette—guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

Cited by 297 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?;Die Urologie;2024-08-23

2. Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches;Pharmaceutics;2024-08-15

3. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update;European Urology;2024-08

4. Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer;World Journal of Urology;2024-07-22

5. Comment prescrire des instillations intra-vésicales de Gemcitabine et Docétaxel ?;Progrès en Urologie - FMC;2024-06